Experience

Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), both wholly owned subsidiaries of Shire,…

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion in aggregate principal amount of senior notes by Halfmoon Parent,…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing 12% senior secured notes due 2020 held by certain holders for new…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in connection with a $4.565 billion senior secured term loan and $1.225…

Davis Polk advised the lenders in connection with a $3 billion 364-day term loan credit facility for AbbVie Inc.  Headquartered in Chicago, Illinois, AbbVie is a global research…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1 billion senior secured term loan A facility, a $1.6 billion senior…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with a series of refinancing transactions that are intended to improve liquidity, extend debt maturities and enable…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which Valeant issued new debt to refinance its shorter term…